Simulations Plus, based in Lancaster, California, offers modeling software and consulting services for drug discovery, employing 192 staff and providing 12 software products and various pharmacokinetic services. Their expertise spans from early drug development to regulatory submissions and includes training solutions for clinical trials.
Simulations Plus (SLP) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Simulations Plus's actual EPS was $0.45, beating the estimate of $0.07 per share, resulting in a 539.20% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
